Search in:

Patient Preference and Adherence Volume 11, 2017 - Issue

Submit an article Journal homepage

Open access

Views

CrossRef citations to date

Altmetric

Original Research

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

Axel Svedbom1 Mapi Group, Stockholm, Sweden

Johan Dalén1 Mapi Group, Stockholm, Sweden

Christopher M Black2 Merck & Co., Inc., Kenilworth, NJ, USA

Sumesh Kachroo2 Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]

Pages 95-106 | Published online: 16 Jan 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (14)

Manuel Pombo‐Suárez, Daniel Seoane‐Mato, Federico Díaz‐González, Luis Cea‐Calvo, Fernando Sánchez‐Alonso, Marta Sánchez‐Jareño, Vega Jovani, Blanca García‐Magallón, Olga Martínez‐González, Cristina Campos‐Fernández, Javier Manero, Cesar Díaz‐Torne, Cristina Bohórquez, Inmaculada Ros‐Vilamajó, Yanira Pérez‐Vera & Isabel Castrejón. (2022) Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Musculoskeletal Care 21:1, pages 189-197.
Crossref

Manuel Pombo‐Suárez, Carlos Sanchez‐Piedra, Dolores Ruiz‐Montesino, Cesar Diaz‐Torne, Vega Jovaní, Luis Cea‐Calvo & Isabel Castrejón. (2021) Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry. Musculoskeletal Care 20:2, pages 403-407.
Crossref

Johan Dalén, Amy Puenpatom, Karin Luttropp, Axel Svedbom & Christopher M. Black. (2021) Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study. Advances in Therapy 39:1, pages 244-255.
Crossref

Nuria Carballo, Enric Garcia-Alzórriz, Olivia Ferrández, María Eugenia Navarrete-Rouco, Xavier Durán-Jordà, Carolina Pérez-García, Jordi Monfort, Francesc Cots & Santiago Grau. (2021) Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study. Frontiers in Pharmacology 12.
Crossref

Dimitrios A. Pappas, Heather J. Litman, Tamara Lesperance, Greg Kricorian, Elaine Karis, Sabrina Rebello, Winnie Hua, Neil A. Accortt & Scott Stryker. (2020) Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. Rheumatology International 41:2, pages 381-390.
Crossref

Johan Dalén, Karin Luttropp, Axel Svedbom, Christopher M. Black & Sumesh Kachroo. (2020) Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. Advances in Therapy 37:9, pages 3746-3760.
Crossref

Axel Svedbom, Johan Dalén, Moa Ivergård, Rebekah H. Borse, Christopher M. Black, Karin Luttropp & Sumesh Kachroo. (2019) The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis. The European Journal of Health Economics 21:1, pages 45-54.
Crossref

Philip J. Mease, Neil A. Accortt, Sabrina Rebello, Carol J. Etzel, Ryan W. Harrison, Girish A. Aras, Mahdi M. F. Gharaibeh, Jeffrey D. Greenberg & David H. Collier. (2019) Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Rheumatology International 39:9, pages 1547-1558.
Crossref

Philip J Mease, Chitra Karki, Mei Liu, YouFu Li, Bernice Gershenson, Hua Feng, Peter Hur & Jeffrey D Greenberg. (2019) Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open 5:1, pages e000880.
Crossref

Maria V. Hernandez, Carlos Sanchez-Piedra, Blanca Garcia-Magallon, Eduardo Cuende, Javier Manero, Cristina Campos-Fernandez, Raquel Martin-Domenech, Javier del Pino-Montes, Sara Manrique, Maria C. Castro-Villegas, Dolores Ruiz-Montesinos, Fernando Sanchez-Alonso, Federico Diaz-Gonzalez, Luis Cea-Calvo & Juan J. Gómez-Reino. (2018) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatology International 39:3, pages 509-515.
Crossref

Nikos Maniadakis, Emese Toth, Michael Schiff, Xuan Wang, Maria Nassim, Boglarka Szegvari, Irina Mountian & Jeffrey R. Curtis. (2018) A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. Advances in Therapy 35:9, pages 1333-1355.
Crossref

Kathrin Ziegelbauer, Karel Kostev, Maximilian Hübinger, Silvia Dombrowski, Michael Friedrichs, Heiko Friedel & Sumesh Kachroo. (2018) The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany. Rheumatology 57:7, pages 1276-1281.
Crossref

Gavin Clunie, Iain B McInnes, Nick Barkham, Helena Marzo-Ortega, Yusuf Patel, Andrew Gough, Jon Packham, Stuart Kyle, Bruce Kirkham, Tom Sheeran, Helen Coope, Anna Bishop-Bailey & Neil McHugh. (2018) Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. Rheumatology Advances in Practice 2:2.
Crossref

Johan Dalén, Axel Svedbom, Christopher M. Black & Sumesh Kachroo. (2017) Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. Rheumatology International 37:12, pages 2049-2058.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

Articles from other publishers (14)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line

Citations (14)

Articles from other publishers (14)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date